CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
GSK239512 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01009060
NCT01009060Phase 2Completed
CompareCT.gov

A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia

GlaxoSmithKline·interventional·Posted Nov 6, 2009·Updated Nov 8, 2017

In Brief

A Phase 2 clinical trial evaluating GSK239512 and Placebo for Schizophrenia. Completed, enrolled 50 participants across 15 sites.

Detailed Summary

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2009
Enrollment StartDec 1, 2009
Primary CompletionAug 10, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.7 years ago

Interventions

GSK239512drug

Histamine H3 Antagonist

Placebodrug

Placebo to match GSK239512